Mineralys Therapeutics, Inc. (MLYS) AI Stock Analysis

• Market Cap: $1.97B
• Dividend Yield: N/A
• Average Volume (3M): 1.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: N/A
• EPS Growth: 9.60%
• Country: US
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 82,399,475
• 10 Day Avg. Volume: 1,371,651
• 30 Day Avg. Volume: 1,174,293
• PEG Ratio: 0.42
• Price to Book (P/B): 3.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.24
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -23.96K
• Enterprise Value/Ebitda: -8.50
• 1Y Price Target: $52.67
• Price Target Upside: 110.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -2.23
• Revenue Forecast (FY): $3.30M

• Rating: 56 Neutral
• Price Target: $28.00 ▲(11.91% Upside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score reflects strong regulatory progress and liquidity/runway from the latest earnings update, but is held back by the lack of revenue and continued cash burn, plus bearish technical momentum and limited valuation support due to ongoing losses.

Positive Factors

Regulatory clarity: NDA accepted

NDA acceptance and a defined PDUFA date materially reduce regulatory timing uncertainty and enable structured commercialization planning. This durable milestone allows focused payer engagement, labeling discussions and launch sequencing well ahead of potential approval, improving strategic optionality.

Strong cash runway

A large cash balance that funds operations into 2028 provides multi-year flexibility to complete regulatory activities, prepare a targeted launch and pursue partnerships without immediate dilution. This reduces near-term financing risk and supports sustained commercial and market-access investments.

Comprehensive positive clinical program

A broad, positive pivotal dataset across multiple trials strengthens the clinical and label case for lorundrostat, lowering development risk. Durable clinical differentiation versus standard therapies supports payer negotiations, formulary access and physician adoption if approved.

Negative Factors

No revenue; widening losses

Persistent lack of product revenue and rising losses create structural dependence on capital markets. Continued cash burn necessitates financing or partnership, risking dilution or constrained investment capacity if markets sour, which can impede long-term commercialization and international expansion.

Missed EXPLORER‑OSA primary endpoint

Failing the OSA primary endpoint limits the ability to claim benefit for sleep apnea comorbidity, narrowing label breadth and potential market segments. This reduces durable differentiation for multimorbidity positioning and may weaken payer willingness to reimburse beyond core hypertension indications.

Partnership and commercial readiness uncertainty

Unsettled partnering and launch staffing plans create execution risk post-approval. Without a partner, scaling commercial infrastructure raises costs and timing risk; with competitors potentially earlier, uncertainty can materially affect market share and international rollout strategies.

Mineralys Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Mineralys does not have publicly established recurring revenue from product sales unless otherwise disclosed; accordingly, detailed ongoing operating revenue streams are null. The company’s funding and cash generation are primarily associated with capital-raising activities typical of pre-commercial biotech companies (e.g., issuing equity in public or private financings, including its initial public offering and subsequent offerings, if any). Potential future sources of revenue—if and when its drug candidates are successfully developed and approved—could include (a) product sales of lorundrostat and any follow-on products, and/or (b) partnering transactions such as licensing deals that may provide upfront payments, development and regulatory milestone payments, sales-based milestones, and royalties; however, specific partnership counterparties, deal economics, and the extent of any collaboration-derived revenue are null if not publicly disclosed in the requested context.

Mineralys Therapeutics, Inc. Financial Statement Overview

Summary

Financial profile is mixed: very weak income statement (no revenue and widening losses) and weak cash flow (ongoing cash burn), partially offset by a strong, debt-free balance sheet with substantially higher equity and liquidity to fund operations.

Income Statement

The income statement remains very weak, with zero revenue across all reported years and consistently large operating and net losses. Losses have expanded materially from 2023 to 2025 (annual net loss roughly -$72M to -$155M), indicating rising R&D/operating spend without offsetting commercial revenue. The main positive is that losses are expected for a development-stage biotech, but the trajectory shows deteriorating profitability and limited visibility into self-funded operations until revenue ramps.

Balance Sheet

The balance sheet is a relative strength. The company reports no debt in recent years and has built a sizable equity base (stockholders’ equity rising to about $647M in 2025 vs. about $191M in 2024), which provides meaningful flexibility to fund operations. Total assets also increased significantly, supporting liquidity. The key weakness is that returns on equity are negative in the latest years due to ongoing losses, and sustained cash burn could pressure equity over time if capital markets tighten.

Cash Flow

Cash flow quality is weak, with consistently negative operating cash flow and negative free cash flow every year. While cash burn improved in 2025 versus 2024 (operating cash outflow about -$142M vs. -$166M), free cash flow still contracted versus prior year based on the provided growth figure (FreeCashFlowGrowth around -16.9% in 2025). Free cash flow is roughly in line with net losses (free cash flow to net income ~1.0), which suggests losses are translating into real cash outflow rather than being mostly non-cash.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-59.00K	-43.00K	0.00	0.00	0.00
EBITDA	-170.60M	-192.36M	-84.66M	-31.48M	-19.38M
Net Income	-154.65M	-177.81M	-71.90M	-29.80M	-19.41M
Balance Sheet
Total Assets	661.81M	205.90M	251.64M	114.44M	11.13M
Cash, Cash Equivalents and Short-Term Investments	656.63M	198.19M	236.57M	110.11M	10.61M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	15.11M	14.65M	10.48M	166.71M	34.05M
Stockholders Equity	646.69M	191.26M	241.15M	-52.27M	-22.93M
Cash Flow
Free Cash Flow	-142.43M	-166.41M	-81.17M	-29.22M	-14.56M
Operating Cash Flow	-142.42M	-166.31M	-81.17M	-29.22M	-14.56M
Investing Cash Flow	-389.75M	114.96M	-160.47M	-21.76M	0.00
Financing Cash Flow	591.00M	116.14M	203.25M	128.02M	23.81M

Mineralys Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 25.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLYS, the sentiment is Negative. The current price of 25.02 is below the 20-day moving average (MA) of 27.69, below the 50-day MA of 30.02, and below the 200-day MA of 29.09, indicating a bearish trend. The MACD of -1.40 indicates Positive momentum. The RSI at 28.82 is Positive, neither overbought nor oversold. The STOCH value of 11.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLYS.

Mineralys Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XENE	62 Neutral	$4.58B	-10.27	-55.81%	―	―	-38.30%
MLYS	56 Neutral	$1.97B	-22.67	-32.94%	―	―	9.60%
APLS	56 Neutral	$2.29B	141.40	8.20%	―	42.11%	―
NAMS	55 Neutral	$3.38B	-19.69	-28.29%	―	―	―
VKTX	52 Neutral	$3.88B	-6.36	-48.04%	―	―	-126.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNTA	48 Neutral	$3.86B	-14.82	-67.68%	―	117.83%	-18.91%

Mineralys Therapeutics, Inc. Corporate Events

Mineralys Reports Mixed Phase 2 Results for Lorundrostat

On March 6, 2026, Mineralys Therapeutics received U.S. Food and Drug Administration acceptance of its New Drug Application for lorundrostat to treat adult patients with hypertension in combination with other antihypertensive drugs, with a target action date set for December 22, 2026. The filing is supported by a clinical program showing clinically meaningful blood pressure reductions and a favorable safety profile, potentially advancing lorundrostat toward commercialization in the sizable uncontrolled and resistant hypertension segments if approved.

In a separate update on March 9, 2026, the company reported topline results from the Phase 2 Explore-OSA exploratory trial in overweight or obese adults with moderate-to-severe obstructive sleep apnea and hypertension, where lorundrostat failed to show a clinically meaningful improvement in apnea-hypopnea index versus placebo after four weeks. However, the study showed statistically and clinically significant reductions in blood pressure and maintained a favorable safety and tolerability profile, suggesting ongoing value for lorundrostat in difficult-to-control hypertensive populations even as its role in sleep apnea-specific endpoints remains unproven.

The most recent analyst rating on (MLYS) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Mineralys Therapeutics, Inc. stock, see the MLYS Stock Forecast page.

Mineralys updates lorundrostat program and upcoming data milestones

On January 6, 2026, Mineralys Therapeutics provided a corporate update detailing significant recent clinical and regulatory milestones for its lead drug candidate, lorundrostat, and announced management’s participation in the LifeSci Partners Corporate Access event scheduled for January 12-14, 2026, in San Francisco. The company disclosed that it had filed a new drug application for lorundrostat with the U.S. Food and Drug Administration in late 2025, following a series of positive clinical readouts, including successful pivotal trials (Launch-HTN and Advance-HTN) in uncontrolled and resistant hypertension and favorable Phase 2 data in chronic kidney disease, as well as ongoing long-term safety evaluation via the Transform-HTN open-label extension. Mineralys also confirmed it remained on track to report topline results in the first quarter of 2026 from its Phase 2 Explore-OSA trial in patients with moderate to severe obstructive sleep apnea and hypertension, a data event that could further support the drug’s positioning as a potential best-in-class therapy for hypertension and comorbid conditions and influence its future regulatory and commercial trajectory.

The most recent analyst rating on (MLYS) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on Mineralys Therapeutics, Inc. stock, see the MLYS Stock Forecast page.